Steroid-Refractory Chronic Graft-versus-Host Disease Treated with Ruxolitinib: A Narrative Review of Symptom Burden and Return to Daily Life. JCCSR [Internet]. 2023 Nov. 4 [cited 2026 Oct. 30];4(1):31-6. Available from: https://pragmajournals.org/index.php/JCCSR/article/view/311